A paper published in Nature Communications has revealed the potential of macrophage-based therapies in the treatment of solid tumours. The research was done by European biotechnology company Cellis and is based on the fact that tumour-infiltrating macrophages play a pivotal role… Read More
Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease - with improved… Read More
Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood,… Read More
Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma rely on transforming growth factor beta-activated kinase 1 (TAK1) for survival and that inhibiting this enzyme leads to the death of the cells. Furthermore, they have demonstrated that it is… Read More
David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More
Offering genetic testing to patients with myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively, say scientists. With effective treatment, more than half of myeloma patients will survive their disease for five years… Read More
Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body. The research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their… Read More
University of Queensland researchers have discovered that immunotherapy, when used to treat people with advanced cancers, also helps reduce sunspots and skin cancers by at least 65%. Over 12 months, researchers monitored 23 patients receiving immunotherapy for unrelated cancers and found the treatment also targeted cancerous and… Read More
Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research. This federated network uses Lifebit’s Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in… Read More
Researchers from the Francis Crick Institute have found that aggressive lung cancer cells can develop their own electric network, like that seen in the nervous system. This unique property could make them less dependent on the environment surrounding the tumour and even spread more easily, say the… Read More
AstraZeneca’s Lynparza (olaparib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. Breast cancer prevalence In Scotland, nearly 5,000 people are diagnosed with breast cancer each… Read More
The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found. These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases… Read More
DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience. Here, looking at cancer burden and research in the sector. Ahead of World Cancer Day in February… Read More
MAIA Biotechnology has shared positive updated data from its THIO-101 Phase II clinical trial evaluating its lead candidate, THIO, in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens. In the trial, THIO was sequenced with Regeneron’s immune checkpoint inhibitor… Read More
Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More
Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics. The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. Akribion is developing an RNA-guided,… Read More
